Abstract: Provided is a composition and method for modulating serotonergic receptor expression, reducing anxiety-like behavior and stress-induced inflammatory response in a pediatric subject, the method including administering to the pediatric subject a nutritional composition including lactoferrin from a non-human source and a prebiotic composition including polydextrose and/or galactooligosaccharides. Further provided is a method for reducing constipation in a pediatric subject by providing a nutritional composition including lactoferrin from a non-human source and a prebiotic composition including polydextrose and/or galactooligosaccharides.

Abstract: The present disclosure generally relates to pediatric nutritional compositions including galacto-oligosaccharide and human milk oligosaccharide or a precursor thereof. Further, the nutritional compositions may include GOS in combination with a first human milk oligosaccharide or precursor thereof and a second human milk oligosaccharide or precursor thereof. The disclosed nutritional compositions advantageously modify gut microbiome and improve select markers of immunity, brain structure, and gut function.

Abstract: The present disclosure is directed to methods for i) promoting gut regeneration, ii) promoting gut maturation and/or adaptation, iii) supporting gut barrier resistance and/or iv) protecting gut barrier function in a pediatric subject comprising administering to the pediatric subject a composition comprising an effective amount of a soluble mediator preparation derived from a late-exponential growth phase of a probiotic batch-cultivation process, such as Lactobacillus rhamnosus GG (LGG). The present methods advantageously provide the gut-protection benefits of LGG soluble mediators without introducing live bacterial culture to individuals with impaired gut barrier function. In some embodiments, the pediatric subject has impaired gut barrier function and/or short bowel syndrome.

Abstract: The present disclosure is directed to methods for i) promoting gut regeneration, ii) promoting gut maturation and/or adaptation, iii) supporting gut barrier resistance and/or iv) protecting gut barrier function in a pediatric subject comprising administering to the pediatric subject a composition comprising an effective amount of a soluble mediator preparation derived from a late-exponential growth phase of a probiotic batch-cultivation process, such as Lactobacillus rhamnosus GG (LGG). The present methods advantageously provide the gut-protection benefits of LGG soluble mediators without introducing live bacterial culture to individuals with impaired gut barrier function. In some embodiments, the pediatric subject has impaired gut barrier function and/or short bowel syndrome.

Abstract: The present disclosure is directed to methods for i) promoting gut regeneration, ii) promoting gut maturation and/or adaptation, iii) supporting gut barrier resistance and/or iv) protecting gut barrier function in a pediatric subject comprising administering to the pediatric subject a composition comprising an effective amount of a soluble mediator preparation derived from a late-exponential growth phase of a probiotic batch-cultivation process, such as Lactobacillus rhamnosus GG (LGG). The present methods advantageously provide the gut-protection benefits of LGG soluble mediators without introducing live bacterial culture to individuals with impaired gut barrier function. In some embodiments, the pediatric subject has impaired gut barrier function and/or short bowel syndrome.

Abstract: A composition and method for enhancing brain development in a pediatric subject, the method including administering to the pediatric subject a nutritional composition having up to about 7 g/100 kcal of a fat or lipid source, wherein the fat or lipid source includes at least about 0.5 mg/100 kcal of milk or non-milk polar lipids; up to about 5 g/100 kcal of a protein source; at least about 15 mg/100 kcal of lactoferrin from a non-human source; about 0.015 g/100 kcal to about 0.15 g/100 kcal of a prebiotic composition including polydextrose and/or galactooligosaccharide; and at least about 5 mg/100 kcal of a source of long chain polyunsaturated fatty acids.

Abstract: The present disclosure generally relates to pediatric nutritional compositions including a prebiotic mixture of galacto-oligosaccharide and/or polydextrose, a probiotic, such as Lactobacillus rhamnosus GG, and human milk oligosaccharides. More particularly, the present disclosure relates to a nutritional composition having: (i) a protein source, (ii) a lipid source, (iii) a carbohydrate source, (iv) a human milk oligosaccharide or a precursor thereof, (v) polydextrose and/or galacto-oligosaccharides, and (vi) a probiotic. The disclosed nutritional compositions advantageously promote the gut-brain axis.

Abstract: The present disclosure generally relates to pediatric nutritional compositions including a prebiotic mixture of galacto-oligosaccharide and/or polydextrose, a probiotic, such as Lactobacillus rhamnosus GG, and human milk oligosaccharides. More particularly, the present disclosure relates to a nutritional composition having: (i) a protein source, (ii) a lipid source, (iii) a carbohydrate source, (iv) a human milk oligosaccharide or a precursor thereof, (v) polydextrose and/or galacto-oligosaccharides, and (vi) a probiotic. The disclosed nutritional compositions advantageously promote the gut-brain axis.

Abstract: The present disclosure relates to method(s) for reducing the risk of visceral pain hypersensitivity, modulating the gut-brain axis, or reducing the local inflammatory response in a subject. The method(s) include providing a nutritional composition that includes Lactobacillus rhamnosus GG (LGG), galacto-oligosaccharide(s) (GOS) and polydextrose (PDX) to the subject. The combination of LGG, GOS, and PDX may exhibit additive or synergistic beneficial health effects when consumed. The nutritional compositions herein are suitable for administration to children and infants.

Abstract: The present disclosure relates to method(s) for reducing the risk of visceral pain hypersensitivity, modulating the gut-brain axis, or reducing the local inflammatory response in a subject. The method(s) include providing a nutritional composition that includes Lactobacillus rhamnosus GG (LGG), galacto-oligosaccharide(s) (GOS) and polydextrose (PDX) to the subject. The combination of LGG, GOS, and PDX may exhibit additive or synergistic beneficial health effects when consumed. The nutritional compositions herein are suitable for administration to children and infants.

Abstract: Provided is a composition and method for modulating serotonergic receptor expression, reducing anxiety-like behavior and stress-induced inflammatory response in a pediatric subject, the method including administering to the pediatric subject a nutritional composition including lactoferrin from a non-human source and a prebiotic composition including polydextrose and/or galactooligosaccharides. Further provided is a method for reducing constipation in a pediatric subject by providing a nutritional composition including lactoferrin from a non-human source and a prebiotic composition including polydextrose and/or galactooligosaccharides.

Abstract: Provided is a composition and method for modulating serotonergic receptor expression, reducing anxiety-like behavior and stress-induced inflammatory response in a pediatric subject, the method including administering to the pediatric subject a nutritional composition including lactoferrin from a non-human source and a prebiotic composition including polydextrose and/or galactooligosaccharides. Further provided is a method for reducing constipation in a pediatric subject by providing a nutritional composition including lactoferrin from a non-human source and a prebiotic composition including polydextrose and/or galactooligosaccharides.

Abstract: A composition and method for enhancing brain development in a pediatric subject, the method including administering to the pediatric subject a nutritional composition having up to about 7 g/100 kcal of a fat or lipid source, wherein the fat or lipid source includes at least about 0.5 mg/100 kcal of milk or non-milk polar lipids; up to about 5 g/100 kcal of a protein source; at least about 15 mg/100 kcal of lactoferrin from a non-human source; about 0.015 g/100 kcal to about 0.15 g/100 kcal of a prebiotic composition including polydextrose and/or galactooligosaccharide; and at least about 5 mg/100 kcal of a source of long chain polyunsaturated fatty acids.

Abstract: A novel method for determining the levels of TGF-?1 or TGF-?2 in a sample of milk, raw protein source, or nutritional composition is provided. The method involves, in some cases, reconstituting the sample; in some cases, centrifuging the sample; activating the sample using particular ratios of sample:acid:base; diluting the sample using particular ratios of sample:buffer agent; and determining the concentration of TGF-?1 in the sample using an ELISA assay.

Abstract: A novel method for determining the bioactivity of TGF-? in a sample of milk, raw protein source, or nutritional composition is provided. The method includes particular reconstitution steps, centrifugation steps, incubation steps, and activation steps. The bioactivity of the TGF-? in the sample may be measured in a HT-2 cell bioassay or a cellomics bioassay.

Abstract: A novel method for determining the bioactivity of TGF-? in a sample of milk, raw protein source, or nutritional composition is provided. The method includes particular reconstitution steps, centrifugation steps, incubation steps, and activation steps. The bioactivity of the TGF-? in the sample may be measured in a HT-2 cell bioassay or a cellomics bioassay.

Abstract: A novel method for determining the levels of TGF-?1 or TGF-?2 in a sample of milk, raw protein source, or nutritional composition is provided. The method involves, in some cases, reconstituting the sample; in some cases, centrifuging the sample; activating the sample using particular ratios of sample:acid:base; diluting the sample using particular ratios of sample:buffer agent; and determining the concentration of TGF-?1 in the sample using an ELISA assay.